Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ATORVASTATIN Cause Intentional product use issue? 157 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 157 reports of Intentional product use issue have been filed in association with ATORVASTATIN (Atorvastatin calcium). This represents 0.2% of all adverse event reports for ATORVASTATIN.

157
Reports of Intentional product use issue with ATORVASTATIN
0.2%
of all ATORVASTATIN reports
16
Deaths
60
Hospitalizations

How Dangerous Is Intentional product use issue From ATORVASTATIN?

Of the 157 reports, 16 (10.2%) resulted in death, 60 (38.2%) required hospitalization, and 9 (5.7%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ATORVASTATIN. However, 157 reports have been filed with the FAERS database.

What Other Side Effects Does ATORVASTATIN Cause?

Type 2 diabetes mellitus (7,556) Myalgia (7,155) Drug hypersensitivity (3,929) Drug ineffective (3,865) Fatigue (3,439) Arthralgia (3,338) Rhabdomyolysis (3,286) Dyspnoea (3,137) Nausea (2,888) Asthenia (2,791)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which ATORVASTATIN Alternatives Have Lower Intentional product use issue Risk?

ATORVASTATIN vs ATORVASTATIN\EZETIMIBE ATORVASTATIN vs ATOSIBAN ATORVASTATIN vs ATOVAQUONE ATORVASTATIN vs ATOVAQUONE\PROGUANIL ATORVASTATIN vs ATRACURIUM

Related Pages

ATORVASTATIN Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue ATORVASTATIN Demographics